A Randomised, Double-blind, Parallel Groups, Placebo-controlled, Multi-centre Trial in Oocyte Donors Assessing the Effects of Barusiban, a Selective Oxytocin Antagonist, on Uterine Contractions on the Day of Embryo Transfer.

Trial Profile

A Randomised, Double-blind, Parallel Groups, Placebo-controlled, Multi-centre Trial in Oocyte Donors Assessing the Effects of Barusiban, a Selective Oxytocin Antagonist, on Uterine Contractions on the Day of Embryo Transfer.

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Jun 2017

At a glance

  • Drugs Barusiban (Primary)
  • Indications Female infertility; Infertility
  • Focus Therapeutic Use
  • Acronyms EFFORT
  • Sponsors Ferring Pharmaceuticals
  • Most Recent Events

    • 21 Apr 2012 Planned number of patients changed from 99 to 100 as reported by European Clinical Trials Database.
    • 16 May 2011 Trial phase change from II/III to II as reported by ClinicalTrials.gov.
    • 07 Jan 2011 Actual initiation date changed from May 2010 to Feb 2010 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top